Products
Suppliers
Sourcing Requests

Post Sourcing Request Exhibition

Home
Products
Supplier
E-Trade Season
Content Hub
Industry Insights
Service & Membership
For Supplier

My Account

My Online Store

My EZSourcing

View Sourcing Requests

Customer Service
For Buyer

Search Products & Suppliers
Products Directory Suppliers Discovery Post EZSourcing
Service
Buyer Sourcing Event Contact Us
Quick links
My Favorites Recent Visit History

free性video西欧极品,伊人依成久久人综合网,中文字幕人妻一区二区三区熟女,男女高潮激烈无遮挡免费观软件 ,成人3d动漫一区二区三区

<del id="a0geg"></del>

<li id="a0geg"><option id="a0geg"></option></li>

<sup id="a0geg"><dd id="a0geg"></dd></sup>

You are here: Industry Insights > Market News > Laurus Labs’ net profit at Rs 48.8 crore in Q2 FY18

Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!

Note: You can unsubscribe from the alerts at any time.

Advertising

New Products

95% up Ascorbyl Palmitate 137-66-6

95% up Ascorbyl Palmitate 137-66-6

Ferric Carboxymaltose 9007-72-1

Ferric Carboxymaltose 9007-72-1

99.5% up by HPLC Salcaprozate sodium/SNAC 203787-91-1

99.5% up by HPLC Salcaprozate sodium/SNAC 203787-91-1

99.5% up by HPLC Menbutone 3562-99-0

99.5% up by HPLC Menbutone 3562-99-0

98.0% up by HPLC Dexamethasone Sodium Phosphate 55203-24-2

98.0% up by HPLC Dexamethasone Sodium Phosphate 55203-24-2

99% up L(+)-Arginine 74-79-3

99% up L(+)-Arginine 74-79-3

Laurus Labs’ net profit at Rs 48.8 crore in Q2 FY18

expressbpdNovember 14, 2017

Tag: Laurus Labs , net profit , Rs

Favorites

Total revenue posted at Rs 538 crore

Hyderabad-based Laurus Labs’ net profit remained flat ?48.8 crore in Q2 FY18, compared to ?48.3 crore in Q2 FY17. The total revenue of company grew 4.3 per cent at Rs 538 crore (Rs 516 crore).

According to Satyanarayana Chava, CEO, Laurus Labs, the ARV (anti-retroviral) business witnessed a significant rise in revenues backed by strong customer offtake. He expects to maintain the momentum for the remaining half of the year.

Previous:Pfizer Q2 net dips to Rs 111 cr

Next:Merck Receives FDA Approval for GONAL-f Prefilled Pen

Related News

CMS Collaborates with SGX to Explore New Paradigms for Industrial Globalization and Pharmaceutical Expansion Overseas across Emerging Markets

ACN NewswireJuly 21, 2025

On July 15 2025, SGX and CMS co-hosted the "Singapore and Emerging Markets Pharmaceutical Industry Growth Forum & CMS SGX Secondary Listing Appreciation Dinner".

InnoCare Announces FDA Approval of Clinical Trial for BCL2 Inhibitor Mesutoclax in AML and MDS

PharmaSourcesJuly 14, 2025

InnoCare Announces Approval of Clinical Trial of a Novel ADC ICP-B794 in China

PharmaSourcesJuly 04, 2025

Laurus Labs’ net profit at Rs 48.8 crore in Q2 FY18 | Pharmasources.com

CanSinoBIO Launches Pneumococcal Vaccine: An Innovative Choice to Safeguard Children's Health

ACN NewswireJune 20, 2025

CanSino Biologics Inc. has developed and launched its 13-valent pneumococcal conjugate vaccine, trade name "iPneucia?", optimized for China’s local pneumococcal epidemiology, aiming to provide more precise and safer protection for Chinese children.

You may like
More>>

Ursolic acid

Immersion Shaker -B

Immersion Shaker -B

Stainless Steel High Quality Activate Carbon Filters Machine

Stainless Steel High Quality Activate Carbon Filters Machine

Handhold 785nm Raman Spectrometers

Handhold 785nm Raman Spectrometers

hydrophobic filters integrity tester

hydrophobic filters integrity tester

Guanosine 5'-(trihydrogendiphosphate), 7-Methyl-3'-O-Methyl-, innerSalt, compd. with N,N-diethyletha

Guanosine 5'-(trihydrogendiphosphate), 7-Methyl-3'-O-Methyl-, innerSalt, compd. with N,N-diethyletha

Ioversol Injection 74.1g/100ml(350 mg iodine per ml), 67.8g/100ml ( 320 mg iodine per ml )

Ioversol Injection 74.1g/100ml(350 mg iodine per ml), 67.8g/100ml ( 320 mg iodine per ml )

Enzymatic conversion of stevia sugar

Enzymatic conversion of stevia sugar

DMT-dC(Bz)-CE Reverse Phosphoramidite

DMT-dC(Bz)-CE Reverse Phosphoramidite

Rosemary Extracts Ursolic Acid 25%

Rosemary Extracts Ursolic Acid 25%

Contact Us

PharmaSources@imsinoexpo.com

Tel: (+86) 400 610 1188

WhatsApp/Telegram/Wechat: +86 13621645194
+86 15021993094

About Us: About PharmaSources; Terms of Service; Privacy Policy; Event Data Sharing Notice; Intellectual Property; Media Partners

Buy: Search Products; Post Sourcing Requests; Search Suppliers; CAS Search

Sell: Member Application; Advertising; Post Products; EZSourcing

Events: CPHI China; PMEC China; Conferences; Search Events

Help: FAQ; Contact Us; Feedback

Copyright 2006-2025 Shanghai Sinoexpo Informa Markets International Exhibition Co. Ltd (All Rights Reserved) 滬ICP備05034851號-182 滬公網(wǎng)安備31010402010101號
Links：
CCCMHPIE SJGLE.com JJGLE.COM JDGLE.COM XIUGLE.COM DENGGLE.COM HPGLE.COM
Follow Us：
Pharma Sources Insight July 2025

PharmaSources Customer Service

<del id="i280w"></del><del id="i280w"><button id="i280w"></button></del>